Clinical trial • Phase I|Phase III • Neurology
etanercept for Alzheimer's disease
Phase I|Phase III trial of etanercept for Alzheimer's disease. 5 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Alzheimer's disease
- Trial Stage
- Phase I|Phase III
- Drug Modality
- Peptide/protein/enzyme
Key dates
- Initial CTIS Submission Date
- 11-03-2024
- First CTIS Authorization Date
- 01-07-2024
Trial design
Phase I|Phase III trial across 1 site in France.
- Target Sample Size
- 5
- Trial Duration For Participant
- 914
Eligibility
Recruits 5 Vulnerable population selected; no details on consent or assent provided in the record..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent provided in the record.
Recruitment
- Planned Sample Size
- 5
- Recruitment Window Months
- 30
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 5
France
- Earliest CTIS Part Ii Submission Date
- 19-04-2024
- Latest Decision Or Authorization Date
- 28-03-2025
- Processing Time Days
- 344
- Number Of Sites
- 1
- Number Of Participants
- 5
Sites
- Site Name
- Hopital Fondation Adolphe De Rothschild
- Department Name
- Neurologie
- Contact Person Name
- Anne Caroline PAPEIX
- Contact Person Email
- cpapeix@for.paris
- Number Of Participants
- 5
Sponsor
Primary sponsor
- Full Name
- Hopital Fondation Adolphe De Rothschild
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- etanercept
- Active Substance
- etanercept
- Modality
- Peptide/protein/enzyme
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.